LGD 4665

Drug Profile

LGD 4665

Alternative Names: 2285921; GSK-2285921; GSK-5291

Latest Information Update: 02 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer GlaxoSmithKline; Ligand Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Thrombopoietin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Immune thrombocytopenic purpura

Most Recent Events

  • 02 Sep 2015 No recent reports on development identified - Phase-II for Immune thrombocytopenic purpura in USA (PO)
  • 18 Dec 2008 LGD 4665 licensed to GlaxoSmithKline worldwide
  • 09 Dec 2008 Interim efficacy & adverse events data from a phase IIa trial in Immune thrombocytopenic purpura presented at the presented at the 50th Annual Meeting and Exposition of the American Society of Hematology (ASH-2008) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top